All In Biotech

Drug Trial Radar · NCT02773030

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 As Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 466 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

466

Actual

Start

Oct 14, 2016

Primary completion

May 9, 2024

Study completion Jul 28, 2028

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
May 16, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • CC-220Drug

    CC-220 at dose specified by cohort dose level from Day 1-21 of each 28-day cycle.

  • DexamethasoneDrug

    Oral DEX 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle. For subjects \>75 years old, oral DEX will be administered at 20 mg on Days 1, 8, 15, and 22 of each 28-day cycle.

  • DaratumumabDrug

    Specified dose on specified days

  • BortezomibDrug

    Specified dose on specified days

  • CarfilzomibDrug

    Intravenous (IV) CFZ administered at a starting dose of 20 mg/m2 on C1D1 and C1D2; and at a dose level specified by cohort dose level thereafter Days 1, 2, 8, 9, 15, 16 of each 28-day cycle.

  • Daratumumab - 16mg/kgDrug

    Daratumumab (DARA) 16mg/kg by intravenous infusion on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.

  • Bortezomib (BTZ)Drug

    Bortezomib 1.3 mg/m\^2 on Days 1, 4, 8 and 11 at cycle 1-8, and Days 1, 8 at cycle ≥9 of each 21-day cycle.

  • Daratumumab- 1800mgDrug

    Daratumumab (DARA) 1800 mg by subcutaneous injection on Days 1, 8, 15, and 22 at cycle 1-2, Days 1, 15 at cycle 3-6, and Day 1 at cycle ≥7 of each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Dose Limiting Toxicities in Part 1.Time frame: From first dose to 28 days post last dose (up to 28 days)
  2. Overall Response Rate (ORR) in Cohort D and Cohort H2Time frame: Approximately on average (Cohort D: 21.14 weeks, Cohort H2: 22.11 Weeks)

Locations

162 sites in 11 countries. Site status is shown where the registry gives one.

  • Local Institution - 102

    Scottsdale, Arizona

  • Mayo Clinic

    Scottsdale, Arizona

  • Local Institution - 107

    Little Rock, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Local Institution - 101

    Atlanta, Georgia

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • Local Institution - 120

    Chicago, Illinois

  • Robert H Lurie Comprehensive Cancer Center NW Univ

    Chicago, Illinois

  • Local Institution - 113

    Fairway, Kansas

  • University of Kansas Cancer Center

    Fairway, Kansas

  • Local Institution - 106

    Baltimore, Maryland

  • University of Maryland School of Med

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Local Institution - 114

    Boston, Massachusetts

  • Local Institution - 115

    Boston, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Dana-Farber/Mass General Brigham Cancer Care, Inc

    Boston, Massachusetts

  • Local Institution - 110

    Boston, Massachusetts

  • Local Institution - 104

    Ann Arbor, Michigan

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Local Institution - 103

    Detroit, Michigan

  • Local Institution - 140

    Grand Island, Nebraska

  • Local Institution - 141

    Grand Island, Nebraska

  • Local Institution - 137

    Omaha, Nebraska

  • Local Institution - 138

    Omaha, Nebraska

  • Local Institution - 131

    Omaha, Nebraska

  • Local Institution - 139

    Papillion, Nebraska

  • Local Institution - 756

    Cherry Hill, New Jersey

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Local Institution - 108

    Hackensack, New Jersey

  • Local Institution - 122

    Mineola, New York

  • NYU Winthrop Hospital

    Mineola, New York

  • Local Institution - 121

    New York, New York

  • New York University School of Medicine

    New York, New York

  • Icahn School of Medicine at Mount Sinai Medical Center

    New York, New York

  • Local Institution - 109

    New York, New York

  • Local Institution - 111

    New York, New York

  • New York Presbyterian Hospital Weil Cornell Medical College

    New York, New York

  • Local Institution - 125

    Rochester, New York

Showing 40 of 162 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.